Trial Profile
A phase IV open label randomised controlled trial of rituximab in induction therapy for living donor renal transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Hydrocortisone; Mycophenolate mofetil; Prednisolone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms ReMIND; RituxiRT
- 27 Jan 2023 Status changed to completed, according to ISRCTN: Current Controlled Trials.
- 28 Mar 2019 Planned End Date changed from 1 Oct 2023 to 1 Oct 2022.
- 28 Mar 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.